Rallybio (RLYB) Other Non Operating Income (2020 - 2026)
Rallybio (RLYB) posted Other Non Operating Income of $254000.0 for Q1 2026, down 98.87% sequentially from $22.5 million in Q3 2025, and up 45.98% YoY from $174000.0 in Q1 2025.
Rallybio (RLYB) Other Non Operating Income (2020 - 2026) Analysis & Trends
Rallybio has reported Other Non Operating Income for 7 years, with the latest figure at $254000.0 in Q1 2026.
- Quarterly Other Non Operating Income rose 45.98% year-over-year to $254000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $22.9 million (up 2942.74% YoY) and the FY2025 annual result came in at $22.8 million, up 2960.62% from the prior year.
- Other Non Operating Income eased to $254000.0 in Q1 2026 per RLYB's latest filing, from $22.5 million in the prior quarter.
- Over five years, Other Non Operating Income peaked at $22.5 million in Q3 2025 and troughed at $31000.0 in Q4 2022.
- A 5-year average of $1.5 million and a median of $115500.0 in 2022 frame the typical range for Other Non Operating Income.
- The sharpest annual moves came in 2022 and 2025: Other Non Operating Income sank 71.56% in 2022, then jumped 8855.78% in 2025.
- Over 5 years, Other Non Operating Income stood at $31000.0 in 2022, then grew by 12.9% to $35000.0 in 2023, then surged by 422.86% to $183000.0 in 2024, then soared by 12183.61% to $22.5 million in 2025, then slumped by 98.87% to $254000.0 in 2026.
- According to Business Quant data, Other Non Operating Income over the past three periods registered $254000.0, $22.5 million, and $118000.0 for Q1 2026, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Rallybio | 94.61 Mn | 94.61 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 424,000.00 |
| Mar 31, 2026 | 254,000.00 |
| Sep 30, 2025 | 22.48 Mn |
| Jun 30, 2025 | 118,000.00 |
| Mar 31, 2025 | 174,000.00 |
| Dec 31, 2024 | 183,000.00 |
| Sep 30, 2024 | 251,000.00 |
| Jun 30, 2024 | 143,000.00 |
| Mar 31, 2024 | 167,000.00 |
| Dec 31, 2023 | 35,000.00 |
| Sep 30, 2023 | 92,000.00 |
| Jun 30, 2023 | 62,000.00 |
| Mar 31, 2023 | 73,000.00 |
| Dec 31, 2022 | 31,000.00 |
| Sep 30, 2022 | 98,000.00 |
| Jun 30, 2022 | 100,000.00 |
| Mar 31, 2022 | 113,000.00 |
| Dec 31, 2021 | 109,000.00 |
| Sep 30, 2021 | 105,000.00 |
| Jun 30, 2021 | -142,000.00 |